Clinical trial Recruiting at 11 sites Interventional Ages 2 to 80

Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes

Official title: Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes

Run by Medtronic MiniMed, Inc. · NCT07864168 · Data updated 2026-11-12

This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.

More Type 1 Diabetes trials

Quick facts

Study typeInterventional
Ages2 Years to 80 Years
SexAll
Enrollment1500 (estimated)
SponsorMedtronic MiniMed, Inc.
Industry-sponsored
Drugs / interventionsradiation
Locations18 sites (Chula Vista, California and 17 other locations)
StatusRecruiting
StartedOctober 5, 2026
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedOctober 20, 2026
Trial IDNCT07864168 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children and adults aged 2–80 years with a clinical diagnosis of type 1 or type 2 diabetes for at least six months (or since aged 2–10 years for younger participants) who are willing to wear the device continuously and provide consent/assent.

Probably not a fit

Patients whose diabetes management does not rely on continuous sensor wear or who cannot tolerate extended sensor use may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multi-center, prospective, single-arm study evaluating the performance of MiniMed's next generation extended wear sensors and accompanying algorithm in both adult and pediatric participants with type 1 or type 2 diabetes. It enrolls participants aged 2 to 80 years and follows them for up to 46 days per subject, with a total study duration of about 24 months to complete all centers. There are no concurrent control subjects; all participants receive the investigational sensor. The trial requires ongoing device wear, fingerstick glucose checks as needed, and informed consent from participants or guardians. Study sites include ProSciento, Stanford University, and Rady Children’s Hospital San Diego, with Medtronic MiniMed, Inc. as lead sponsor.

Why it matters

Potential benefit: If successful, participants may benefit from improved glucose sensing through the extended wear sensor, potentially aiding diabetes management.

How similar studies have gone: Previous studies of continuous glucose sensing technologies have shown feasibility and accuracy in diabetes care, though this specific extended wear sensor/algorithm is being evaluated in a single-arm design.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age 2-80 years at time of screening.
2. Has a clinical diagnosis of diabetes as stipulated according to the following age group:

   1. Age 2-10 years: Has a clinical diagnosis of T1D or T2D as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
   2. Age 11-80 years: Has a clinical diagnosis of T1D or T2D for 6 months or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
3. Subject or parent(s)/ guardian(s)/ caregiver(s) is/are literate and able to read the language offered in the study materials.
4. Is willing to provide informed consent/assent for participation.
5. If participating in BGA FST, has adequate venous access as assessed by investigator or appropriate staff.
6. Is willing to perform fingerstick blood glucose measurements as needed.
7. Is willing to wear the study devices continuously throughout the study.
8. Subject or parent(s)/guardian(s)/caregiver(s) is/are willing to complete the requirements for diary data entry, as applicable.
9. If participating in glycemic challenges, has met the following conditions:

   1. Been using insulin for at least 3 months
   2. A relatively stable insulin-to-carbohydrate ratio(s) and insulin sensitivity factor(s) for at least one month per investigator assessment Subjects who do not meet the above conditions can be included in the study, however, will participate in the FST under observation only (no glycemic challenges).

Exclusion Criteria:

1. Unable to consent due to a mental or intellectual disability.
2. Has a history of 1 or more episodes of severe hypoglycemia during the 6 months prior to screening visit.
3. Has had a hypoglycemic seizure within the past 6 months prior to screening visit.
4. Has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
5. Has a history of 1 or more episodes of DKA in the last 6 months prior to screening visit.
6. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.
7. Has a history of a seizure disorder.
8. Has a central nervous system or cardiac disorder resulting in syncope.
9. Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
10. Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
11. Currently pregnant or planning to become pregnant during the time period of study participation

    1. A negative pregnancy test will be required for all females of child-bearing potential at time of screening
    2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of contraception that is being used is reliable
12. Has diagnosis of adrenal insufficiency.
13. Is using hydroxyurea at time of screening or plans to use it during the study.
14. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study. (Please note participation in an observational study is acceptable.)
15. Has a planned procedure involving the use of a Magnetic Resonance Imaging (MRI), diathermy devices, or other devices that generate strong magnetic fields (e.g., x-ray, CT scan, or other types of radiation) during the study wear period.
16. Has elective surgery planned that requires general anesthesia during the course of the study.
17. T2D: Is using insulin secretagogue.
18. Is, at the discretion of the investigator, abusing drugs or alcohol
19. Age 7-80 years: has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that prior blood draw from routine care may be used as long as the prior blood draw was done within 3 months prior to screening and report of lab placed with subject source documents).
20. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
21. Has had any of the following cardiovascular events more than 1 year prior to screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. However, subject may participate at the discretion of the investigator and with clearance from the cardiologist.
22. Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.
23. Is a member of the research staff involved with the study.
24. Is a sponsor employee or their immediate family member (excluding adult children and/or adult siblings).

Where it's running

  • ProSciento
    Chula Vista, California, United States
    Recruiting
  • Sansum Diabetes Research Institute
    Santa Barbara, California, United States
    Recruiting
  • Diablo Clinical Research, Inc.
    Walnut Creek, California, United States
    Recruiting
  • Barbara Davis Center for Diabetes
    Aurora, Colorado, United States
    Recruiting
  • Barbara Davis Center for Diabetes
    Aurora, Colorado, United States
    Recruiting
  • Atlanta Diabetes Associates
    Atlanta, Georgia, United States
    Recruiting
Show 12 more locations
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho, United States
    Recruiting
  • Texas Diabetes and Endocrinology
    Austin, Texas, United States
    Recruiting
  • Diabetes and Glandular Disease Clinic
    San Antonio, Texas, United States
    Recruiting
  • University of Virginia Health System
    Charlottesville, Virginia, United States
    Recruiting
  • Rainier Clinical Research Center
    Renton, Washington, United States
    Recruiting
  • Stanford University
    Palo Alto, California, United States
    Not yet recruiting
  • Rady Children's Hospital - San Diego
    San Diego, California, United States
    Not yet recruiting
  • University of California San Francisco UCSF The Madison Clinic for Pediatric Diabetes
    San Francisco, California, United States
    Not yet recruiting
  • Yale University School of Medicine
    New Haven, Connecticut, United States
    Not yet recruiting
  • University of Florida
    Gainesville, Florida, United States
    Not yet recruiting
  • University of South Florida (USF) Diabetes and Endocrinology Center
    Tampa, Florida, United States
    Not yet recruiting
  • Seattle Children's
    Seattle, Washington, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.